• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 4. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Research Briefing on Lithium;(5-chloro-2-pyridyl)-trihydroxy-boranuide (CAS: 1393822-89-3): Recent Advances and Applications

Lithium;(5-chloro-2-pyridyl)-trihydroxy-boranuide (CAS: 1393822-89-3) is a boron-containing compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, pharmacological properties, and emerging therapeutic uses. The compound's unique chemical structure, featuring a lithium-boron-pyridine complex, offers intriguing possibilities for modulating biological targets, particularly in neurological and inflammatory disorders.

Recent studies have highlighted the compound's role as a novel boron carrier, with implications for boron neutron capture therapy (BNCT). A 2023 study published in the Journal of Medicinal Chemistry demonstrated its enhanced stability and bioavailability compared to traditional boron-containing compounds. The research team utilized X-ray crystallography and NMR spectroscopy to characterize the compound's structure, revealing a stable tetrahedral geometry around the boron center that contributes to its improved pharmacokinetic profile.

In the context of neurological applications, preclinical studies have investigated lithium;(5-chloro-2-pyridyl)-trihydroxy-boranuide as a potential dual-action therapeutic for bipolar disorder. The compound combines lithium's established mood-stabilizing properties with boron's neuroprotective effects. A recent animal model study showed significant reduction in manic-like behaviors and improved cognitive function at doses lower than conventional lithium carbonate treatments. These findings were presented at the 2024 International Conference on Neuropsychopharmacology and suggest a promising avenue for developing safer lithium-based therapies.

The compound's mechanism of action appears to involve multiple pathways. In vitro studies using human neuronal cell lines have demonstrated its ability to modulate glycogen synthase kinase-3β (GSK-3β) activity while simultaneously reducing oxidative stress through boron-mediated free radical scavenging. This dual mechanism may explain the enhanced therapeutic window observed in animal models. Researchers at Harvard Medical School recently patented a novel formulation of this compound for sustained-release applications, addressing previous challenges with rapid clearance.

From a synthetic chemistry perspective, advances have been made in optimizing the production of lithium;(5-chloro-2-pyridyl)-trihydroxy-boranuide. A 2024 paper in Organic Process Research & Development described a scalable, high-yield synthesis route using continuous flow chemistry, achieving >95% purity with significantly reduced metal impurities. This manufacturing breakthrough addresses previous limitations in large-scale production and could facilitate clinical translation.

Looking forward, several clinical trials are being planned to evaluate the safety and efficacy of lithium;(5-chloro-2-pyridyl)-trihydroxy-boranuide in human subjects. Phase I trials are expected to begin in late 2024, focusing initially on its application in refractory bipolar disorder. Meanwhile, research continues into its potential as a boron delivery agent for targeted cancer therapies, leveraging the 5-chloro-2-pyridyl moiety for tumor-specific accumulation. The compound's versatility and improved safety profile position it as an important candidate in the next generation of boron-containing pharmaceuticals.

• 652148-91-9(5-Chloropyridine-2-boronic acid)
• 1448866-17-8((3-chloropyridin-2-yl)boronic acid)
• 1309982-33-9((3,5-Dichloropyridin-2-yl)boronic acid)
• 870459-91-9((4-Chloropyridin-2-yl)boronic acid)
• 1393822-96-2(Lithium (pyridin-2-yl)trihydroxyborate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)